Shorter overall survival (OS) was associated with Glut-1 positivity (P = 0.023), tumor phenotype (HER2 and TNBC; P < 0.001) and tumor metabolic type (mixed type; P = 0.045) (Figure 2). The gene discussed is SLC2A1; the disease is neoplasm.